Immune Signaling Molecule CCL17 Drives Inflammatory Pain Through Substance P and CGRP
The chemokine CCL17, produced by macrophages under GM-CSF control, drives inflammatory and arthritic pain through a pathway requiring nerve growth factor, CGRP, and substance P.
Quick Facts
What This Study Found
A GM-CSF→CCL17 pathway in macrophages drives inflammatory pain through nerve growth factor, CGRP, and substance P signaling in non-bone-marrow-derived cells.
Key Numbers
CCL17 from macrophages (GM-CSF-dependent); acts on CCR4+ non-BM cells; NGF, CGRP, substance P all required for pain
How They Did This
Multiple mouse inflammation and arthritis models using Ccl17 reporter mice, radiation chimeras, and pharmacological blockade of downstream mediators (NGF, CGRP, substance P).
Why This Research Matters
Identifying that CCL17 funnels through neuropeptides like CGRP and substance P to cause pain reveals multiple potential drug targets for inflammatory and arthritic pain.
The Bigger Picture
CGRP-blocking drugs (like migraine medications) and substance P antagonists already exist. Understanding how CCL17 engages these pathways could expand their use to arthritic and inflammatory pain.
What This Study Doesn't Tell Us
Mouse models only; group sizes not specified; the specific CCR4+ non-bone-marrow cells responding to CCL17 were not fully identified.
Questions This Raises
- ?Would CGRP-blocking antibodies (used for migraine) also reduce CCL17-driven arthritic pain?
- ?Which specific non-bone-marrow cell types express CCR4 and mediate the pain response?
- ?Does this pathway operate similarly in human inflammatory conditions?
Trust & Context
- Key Stat:
- 3 mediators required NGF, CGRP, and substance P are all necessary for CCL17-driven inflammatory pain
- Evidence Grade:
- Moderate — robust mechanistic animal study using multiple models and reporter mice, but no human data.
- Study Age:
- Published in 2020; CGRP-targeting therapies have since expanded significantly.
- Original Title:
- CCL17 in Inflammation and Pain.
- Published In:
- Journal of immunology (Baltimore, Md. : 1950), 205(1), 213-222 (2020)
- Authors:
- Lee, Kevin M-C, Jarnicki, Andrew, Achuthan, Adrian, Fleetwood, Andrew J, Anderson, Gary P, Ellson, Christian, Feeney, Maria, Modis, Louise K, Smith, Julia E, Hamilton, John A, Cook, Andrew
- Database ID:
- RPEP-04932
Evidence Hierarchy
Frequently Asked Questions
What is CCL17?
A chemokine (immune signaling protein) produced by macrophages that recruits certain immune cells and, as this study shows, also drives pain signaling.
How does this relate to CGRP migraine drugs?
The same CGRP molecule involved in migraine is required for CCL17-driven inflammatory pain, suggesting CGRP-blocking drugs might help with arthritis pain too.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04932APA
Lee, Kevin M-C; Jarnicki, Andrew; Achuthan, Adrian; Fleetwood, Andrew J; Anderson, Gary P; Ellson, Christian; Feeney, Maria; Modis, Louise K; Smith, Julia E; Hamilton, John A; Cook, Andrew. (2020). CCL17 in Inflammation and Pain.. Journal of immunology (Baltimore, Md. : 1950), 205(1), 213-222. https://doi.org/10.4049/jimmunol.2000315
MLA
Lee, Kevin M-C, et al. "CCL17 in Inflammation and Pain.." Journal of immunology (Baltimore, 2020. https://doi.org/10.4049/jimmunol.2000315
RethinkPeptides
RethinkPeptides Research Database. "CCL17 in Inflammation and Pain." RPEP-04932. Retrieved from https://rethinkpeptides.com/research/lee-2020-ccl17-in-inflammation-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.